Acquisition of Admune Therapeutics


Our attorneys advised longtime client Novartis in its acquisition of Admune Therapeutics, a Massachusetts-based clinical stage biotechnology company. The deal, announced October 21, broadens Novartis’ immuno-oncology pipeline. Terms of the deal were not disclosed.

With products available in more than 180 countries around the world, Basel, Switzerland-headquartered Novartis is the only global company with leading positions in innovative medicines, eye care and cost-saving generic pharmaceuticals.

Email Disclaimer